MX2023003264A - Inhibidores de cdk y su uso como productos fármaceuticos. - Google Patents

Inhibidores de cdk y su uso como productos fármaceuticos.

Info

Publication number
MX2023003264A
MX2023003264A MX2023003264A MX2023003264A MX2023003264A MX 2023003264 A MX2023003264 A MX 2023003264A MX 2023003264 A MX2023003264 A MX 2023003264A MX 2023003264 A MX2023003264 A MX 2023003264A MX 2023003264 A MX2023003264 A MX 2023003264A
Authority
MX
Mexico
Prior art keywords
pharmaceuticals
cdk inhibitors
compounds
formula
cdk
Prior art date
Application number
MX2023003264A
Other languages
English (en)
Spanish (es)
Inventor
Andrew W Buesking
Andrew Paul Combs
Jincong Zhou
Ryan Holmes
Sarah Pawley
Xiaowei Wu
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2023003264A publication Critical patent/MX2023003264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023003264A 2020-09-21 2021-09-21 Inhibidores de cdk y su uso como productos fármaceuticos. MX2023003264A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063081126P 2020-09-21 2020-09-21
US202163221959P 2021-07-15 2021-07-15
PCT/US2021/051226 WO2022061273A1 (en) 2020-09-21 2021-09-21 Cdk inhibitors and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
MX2023003264A true MX2023003264A (es) 2023-06-06

Family

ID=78087595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003264A MX2023003264A (es) 2020-09-21 2021-09-21 Inhibidores de cdk y su uso como productos fármaceuticos.

Country Status (11)

Country Link
US (2) US11685744B2 (cg-RX-API-DMAC7.html)
EP (1) EP4214213A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023543433A (cg-RX-API-DMAC7.html)
KR (1) KR20230123919A (cg-RX-API-DMAC7.html)
CN (1) CN116583283B (cg-RX-API-DMAC7.html)
AU (1) AU2021345423A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196016A1 (cg-RX-API-DMAC7.html)
IL (1) IL301509B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023003264A (cg-RX-API-DMAC7.html)
WO (1) WO2022061273A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304541B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020345950A1 (en) 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
AU2022383957A1 (en) * 2021-11-15 2024-05-30 Erasca, Inc. Thiophene ulk1/2 inhibitors and their use thereof
WO2023133229A2 (en) * 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
IL315671A (en) * 2022-03-23 2024-11-01 Prelude Therapeutics Inc Polymorphic compounds and their uses
TW202400168A (zh) * 2022-05-04 2024-01-01 美商艾瑞斯卡公司 噻吩ulk1/2抑制劑及其用途
WO2024051717A1 (zh) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
WO2025128616A1 (en) * 2023-12-12 2025-06-19 Genesis Therapeutics, Inc. Compounds for treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
WO2005014572A1 (en) * 2003-08-08 2005-02-17 Pharmacia Italia S.P.A. Pyrimidylpyrrole derivatives active as kinase inhibitors
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
ES2389673T3 (es) * 2007-09-28 2012-10-30 Nerviano Medical Sciences S.R.L. Derivados de pirrolopirimidina sustituidos, procedimiento para su preparación y su uso como inhibidores de quinasas
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2017114351A1 (en) * 2015-12-27 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
TWI736578B (zh) * 2016-02-06 2021-08-21 大陸商上海複尚慧創醫藥研究有限公司 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用
MA49840A (fr) 2017-08-09 2020-06-17 Prelude Therapeutics Inc Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
CA3092357A1 (en) 2018-03-14 2019-09-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US12133841B2 (en) 2018-05-22 2024-11-05 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CN112457326B (zh) * 2019-09-06 2022-02-15 上海凌达生物医药有限公司 一类芳香杂环并内酰胺类化合物、制备方法和用途

Also Published As

Publication number Publication date
US11685744B2 (en) 2023-06-27
CN116583283B (zh) 2026-03-17
JP2023543433A (ja) 2023-10-16
US20230357265A1 (en) 2023-11-09
IL301509B1 (en) 2026-01-01
EP4214213A1 (en) 2023-07-26
CA3196016A1 (en) 2022-03-24
ZA202304541B (en) 2025-03-26
AU2021345423A1 (en) 2023-05-11
US20220089608A1 (en) 2022-03-24
IL301509B2 (en) 2026-05-01
WO2022061273A1 (en) 2022-03-24
KR20230123919A (ko) 2023-08-24
CN116583283A (zh) 2023-08-11
IL301509A (en) 2023-05-01
AU2021345423A9 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
ZA202304541B (en) Cdk inhibitors and their use as pharmaceuticals
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
WO2022125616A8 (en) Dialkyl tryptamines and their therapeutic uses
ZA202005325B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
MX2025002929A (es) Compuestos de objetivo brm y metodos de uso asociados
MY209034A (en) Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA200700138A1 (ru) Замещённые индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
MX2023011864A (es) Inhibidores de dihidroorotato deshidrogenasa deuterados.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2023005039A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2025011346A (es) Compuestos de quinolinona amida y usos de los mismos
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية